Curated News
By: NewsRamp Editorial Staff
August 25, 2026
B2i Digital Showcases Lakewood-Amedex's Novel Antimicrobial Class
TLDR
- Lakewood-Amedex's Nu-3 targets resistant bacteria in diabetic foot ulcers, an unmet need with a large patient population and significant market potential.
- Nu-3 works by disrupting bacterial cell membranes within minutes, showing no resistance in tests, and is entering Phase 2a with three dose levels.
- Nu-3 offers hope for millions with diabetic foot ulcers, aiming to reduce infections and amputations by providing a new treatment option.
- B2i Digital features Lakewood-Amedex, a biotech with 72 patents, as it prepares trials for a novel antimicrobial gel.
Impact - Why it Matters
This news matters because antimicrobial resistance is a growing global health crisis, rendering many existing antibiotics ineffective. Lakewood-Amedex's Bisphosphocin® class offers a novel mechanism that could combat resistant infections like MRSA, which are particularly dangerous in diabetic foot ulcers. The upcoming Phase 2a trial will provide crucial data on safety and efficacy, potentially leading to a new treatment option for a condition that affects millions and often results in amputation. For investors, this represents an early opportunity to engage with a promising clinical-stage company addressing an unmet medical need.
Summary
B2i Digital, Inc. has welcomed Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) as its newest Featured Company, spotlighting the clinical-stage biotech's innovative Bisphosphocin® class of antimicrobials. The partnership aims to introduce Lakewood-Amedex's science and upcoming Phase 2a trial to a broader investment audience through B2i Digital's extensive media network and capital markets connections. The core of the campaign centers on Nu-3, a topical gel targeting infected diabetic foot ulcers (iDFU), a condition affecting millions worldwide with growing antimicrobial resistance concerns.
Lakewood-Amedex's Bisphosphocin® compounds work by physically disrupting bacterial cell membranes, a mechanism that may overcome resistance issues plaguing traditional antibiotics. In preclinical studies, Nu-3 demonstrated a high barrier to resistance and broad-spectrum activity, including against MRSA. The upcoming Phase 2a trial will evaluate safety and efficacy at three concentrations (2%, 5%, 10%) in patients with infected diabetic foot ulcers, with renowned clinician David G. Armstrong serving as Study Chair. The company's robust IP portfolio includes 72 issued patents, and it recently listed on Nasdaq, signaling readiness for clinical advancement.
B2i Digital's CEO, David Shapiro, emphasized the urgent need for new antimicrobial approaches, while Lakewood-Amedex's CEO, Kelvin Cooper, highlighted the opportunity to explain their science to a wider investor base. The collaboration underscores the importance of addressing antibiotic resistance and bringing novel therapies to market. For more details, visit the featured company profile at https://b2idigital.com/featured-companies.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, B2i Digital Showcases Lakewood-Amedex's Novel Antimicrobial Class
